Proton therapy offers dosimetric advantage of decreased dose to non-target tissues. This study explored the potential benefits of proton radiation therapy versus photon based intensity modulated radiation therapy (IMRT) for patients with low grade gliomas (LGG) through dosimetric comparison and biological modeling of potential radiation-induced toxicities. Eleven patients were treated with fractionated proton radiation therapy on a prospective protocol assessing for feasibility and treatment toxicity of proton radiation therapy in patients with LGG.
Introduction
Low-grade gliomas (LGG) account for less than 10% of newly diagnosed central nervous system (CNS) tumors and strike primarily young adults in the age group of 20-44 (1) . Radiation therapy is one of the few therapeutic options available for these patients. The timing of radiation therapy is a much-debated issue, with implementation either at the time of initial diagnosis or at the time of tumor progression. Patient selection for upfront treatment is variable but often are patients at age .40, with unresectable or large tumors, with persistent tumor related symptoms, or with tumors affecting both hemispheres (2). It has been shown that radiation therapy in tandem with surgical resection yields a progression free survival benefit for LGG patients (3). In addition, a favorable subset of LGG patients harboring 1p/19q codeletion may live beyond a decade and may benefit most from therapies that minimize side effects (4).
Because LGG patients are reasonably long-term survivors, potential late effects of radiation are of great importance. Potential toxicities vary depending upon tumor location but may include persistent fatigue, cognitive deficiencies in memory and executive function, hypopituitarism, hearing loss, dryness of the eye, visual deficit, and a very low but possible risk of a secondary tumor. These effects may be largely due to current limitations in the treatment delivery. An increasingly common method of radiation delivery for LGG is intensity modulated radiation therapy (IMRT), which due to its iterative dosimetric properties may be an effective way of creating conformal dose distributions and improving tumor coverage while limiting the dose to critical structures. It utilizes a target-specific computerized optimization of photon pencil beams in order to shape the dose. IMRT has shown an increase benefit of normal tissue sparing for large or moderately sized irregularly shaped targets in CNS studies over both 3D-conformal photon beam treatment and photon stereotactic radiotherapy (5-7). The technical advancements seen in IMRT remain limited by its associated low dose radiation bath to the non-target tissues, which in the setting of LGG is largely the brain parenchyma.
Proton therapy provides an option to address the normal tissue dose bath limitation of IMRT. Proton therapy has proven to be an effective means of targeting tumor while reducing dose to surrounding critical structures and other normal tissue. Protons exhibit the properties of a finite beam path length and of the Bragg peak, depositing their dose payload at the end of their chosen beam range. This serves to significantly reduce the "dose bath" to surrounding healthy tissue that is a characteristic tradeoff of IMRT to achieve high dose conformity. The absence of dose beyond the modulated distance, often referred to as the exit dose, also enables treatment with more direct, and often advantageous beam directions, as there is less concern for critical structures in the wake of the target (8).
The physical characteristics of proton therapy may be beneficial in the treatment optimization for LGG. This study compares both the physical dosimetric differences and the estimated clinical late effects of treatment of LGG using proton therapy and IMRT, in an attempt to quantify the difference and potential clinical advantages of proton radiation over IMRT. A clinically significant reduction in toxicity may translate to increase use of upfront radiation therapy and a promising new way to manage the LGG patient population.
Materials and Methods

Case Selection
Eleven patients with LGG were treated with fractionated proton therapy as a pilot study evaluating the feasibility and potential clinical benefits of proton radiation. There was no anatomical criteria used in the selection process for the 11 cases in this study, rather subjects were selected as consecutive cases in the enrollment of the study. For this comparison study, IMRT plans were generated from the same CT and compared to the delivered proton plans.
Patients were immobilized with a non-invasive, modified Gill-Thomas-Cosman stereotactic frame or a thermoplastic facemask and CT scans were acquired with 2.5 mm axial slices. Target volumes and all critical structures were defined with the aid of Focal software (Elekta, Stockholm, Sweden) to fuse the CT data with T1 weighted and T2 weighted MRI sequences. Both pre and post surgical MR studies were used, with the best representation of the target definition used for the purpose of identifying structures. The gross target volume (GTV) was defined as the surgical cavity, any gadolinium enhancement, and T2 hyper-intense findings. The clinical target volume (CTV) was defined as a 1.5 cm expansion around the GTV, excluding critical structures that were not apparently involved such as the optic chiasm and respecting anatomical boundaries such as the skull or falx. All critical normal structures were defined by a neuro-anatomist.
Proton Planning
Fractionated proton plans were created using an in-housemodified CMS XiO planning system (Elekta, Stockholm, Sweden). Each plan utilized two to four passively scattered proton beams prescribed to 54 Gy (RBE) in 30 fractions of 1.8 Gy (RBE). The Gy (RBE) unit accounts for a radiobiological effect correction factor of 1.1 for proton radiation. All plans were normalized to the 95% isodose line. It is important to note that the conventional photon PTV is not applicable to protons because of the differences in the depth dose profiles. Except for critical structure avoidance, target collimation margins were applied to position the 95% isodose line 3 mm outside the target edge for each beam. A 3.5% range and modulation uncertainty was added to each beam and a 3 mm range compensator smearing was applied to account for the impact of set-up uncertainties on the distal fall-off of the Bragg peak. Daily pre-treatment kV imaging was performed prior to every field to confirm alignment prior to beam delivery.
IMRT Planning
IMRT treatment plans were created with the CMS XiO planning system (Elekta, Stockholm, Sweden) using the same CT data and outlined structures. All plans employed 6 MV coplanar photon beams. The majority of plans employed fivefields. Beam angles were chosen to minimize entry/exit dose to critical structures and to facilitate optimization. Plans were constrained to the same critical structure and CTV dose deliberations. A 3 mm expansion was added to the CTV to create a PTV, which was used for planning optimization. This allowed for a realistic plan comparison, taking into account the differences of both treatment modalities. The normalization was set to 100% and adjusted iteratively during the planning process to achieve the optimal target dose with minimization of dose to critical structures.
Dosimetric Comparisons
Dose volume histograms (DVH) were obtained for both treatment plans, which included CTV, whole brain, brainstem, pituitary gland, cochleas, optic chiasm, optic nerves, lacrimal glands and temporal lobes. These data were then used to estimate the toxicity risk for IMRT and proton radiation therapy by calculating the equivalent uniform dose (EUD) and modeling the normal tissue complication probability (NTCP). The risk of secondary tumors was also estimated for each modality.
Analysis
Equivalent Uniform Dose (EUD):
To compare tissue dose between plans and therefore estimate treatment related morbidity, an Equivalent Uniform Dose (EUD) model described by Niemierko was used (9, 10). EUD models the uniform dose, which results in the same probability of normal tissue morbidity as the actual inhomogeneous dose distribution. This allows for a more consistent manner of assessing treatment related morbidity as opposed to just mean or maximum dose. Generalized EUD is given by:
v i is fractional volume, D i is dose bin and the a value is an organ and endpoint-specific value that takes into account the organ's response to inhomogeneous dose. The rank order of treatment modality is greatly insensitive to the exact value of the EUD parameter "a". Specifically, changing the value of "a" changes the resultant value of EUD proportionally for both modalities keeping the rank order unchanged. Thus, a Wilcoxon sign-rank test was performed to compare organ specific EUD and particularly the mean dose between each treatment modality. All EUD calculations were performed using Stata 11.2 (StataCorp College Station, Texas).
Normal Tissue Complication Probability (NTCP):
Normal Tissue Complication Probability was estimated using a logistic form of the dose-response function with EUD as a measure of inhomogeneously delivered dose (11):
Where D 50 is the dose corresponding to 50% chance of complication and g 50 is the slope of the dose-response curve.
Second Tumor Risk:
The excess risk of radiation-induced second tumors in the brain was calculated using the method proposed by Schneider (12) . The method is based on the concept of Organ Equivalent Dose (OED) for radiation-induced cancer. The OED is calculated based on the whole brain dose-volume histogram.
Results
Five of the 11 patients had temporal lobe lesions, two had frontal lobe lesions, two had frontotemporal lesions, three patients had lesions located in the parietal region, and one patient had a temporoparietal lesion. The mean target volume was 162.2 (range 22.5-390.3) cubic centimeters. The mean raw dose to the CTV and each critical structure along with the maximum and minimum raw doses for each modality can be found in Table I . For every critical structure, the mean proton dose is less than the mean IMRT dose. Additionally, the proton EUD for all structures is between 10-20 Gy lower on average than the EUD for IMRT with the exception of the whole brain dose difference of 2 Gy (Table I ). The greatest differences are seen in the pituitary gland having a 22 Gy lower average EUD with proton radiation than IMRT and the optic nerves having an average of 15.5 Gy lower EUD with proton radiation than IMRT.
The difference between proton therapy critical structure doses versus those of IMRT is also readily apparent when examining the critical structures located contralateral to the target site, seen most distinctly when comparing temporal lobe doses (Table II) . For the 7 patients with lesions located in the right hemisphere, in 6 of these patients, the left temporal lobe received significantly less dose (negligible dose in 4 cases) with proton therapy than with IMRT. Likewise for the four patients with lesions in the left hemisphere, all of the patients had negligible dose in the contralateral right temporal lobe for the proton plan, while the IMRT dose was significantly higher. The use of non-coplanar IMRT beams would have resulted in lower contra-lateral doses but also resulted in larger normal tissue low dose volumes.
If we explore the optic structures based on the side of lesion location, a similar trend emerges (Table III) . There are two patients (#8 and 9) for whom the dose to the optic structures is negligible for both the proton and the IMRT plans due to the posterior temporal and parietal locations of the targets significantly spaced from anterior critical structures. Aside from these patients, all patients with tumors in the right hemisphere had significantly lower doses delivered to the left side optic pathway structures with proton therapy than with IMRT. This is also true for the ipsilateral right-sided optic structures for all patients with right-sided tumors but one. For patients with tumors in the left hemisphere, the same significant lower dose with proton therapy is seen as compared to IMRT for both contralateral visual structures and the ipsilateral left sided optic system.
Likewise, the individual patient mean doses to critical structures along the midline neuro-axis, that is, the brainstem, optic chiasm and pituitary gland, follow this trend (Table IV) . All 11 patients exhibit lower doses to the brainstem for the proton plan. Three of these cases have dose differences within 5 Gy (RBE) between the proton and IMRT plans. The dose to the optic chiasm is less for the proton plan in 10 of the 11 patients, with 3 of these cases resulting in proton and IMRT plans within 5 Gy (RBE). The one patient who had a slightly higher proton dose was within 1 Gy (RBE) of the IMRT plan. For all patients, the dose to the pituitary gland is less for the proton plan than the IMRT plan, and significantly so in 9 of the 11 cases.
The difference between NTCP for protons and IMRT is much smaller. For most cases, the corresponding NTCP is negligible for both modalities, even if the proton dose is lower (Table I ). The only structures in which there is a notable difference are the cochleas, with a higher NTCP for IMRT compared to proton radiation of 10% and 5%, respectively. The pituitary gland has a 4% higher average NTCP for IMRT compared to proton radiation. In regards to secondary tumor risk, the mean excess risk of proton radiation-induced second tumor in the brain per 10,000 cases per year is 47 (range 11-83), while the mean risk for IMRT is 106 (range 70-134). The mean ratio of excess risk of IMRT to protons is 2.2 (range 1.6-6.5), demonstrating that the risk of second tumors is higher for IMRT as expected. Figures 1 and 2 are examples of treatment plans and DVH plots for two cases. Marked sparing of the brain was achieved in both cases with protons as compare to IMRT. Dose sparing of critical structures such as the optic chiasm and cochlea is achieved with proton therapy.
Discussion
Proton therapy was found to have the greatest margin of benefit in normal tissue dose sparing over IMRT in patients with tumors in close proximity to critical structures. The superior dosimetry of proton therapy over IMRT is readily apparent when examining the critical structures located contralateral to the target site. The most obvious display of this benefit is in the temporal lobe doses (Table II) . In most cases, proton therapy also achieves better sparing of critical structures on the same side as the tumor. Whether the dosimetric difference seen translates to a clinical difference is perhaps the most relevant question.
A two-fold higher risk of secondary intracranial tumors was found with IMRT when compared to proton therapy. This is an important feature to consider for this patient population of young adults who are reasonably long term survivors. In comparison, the NTCP for both modalities were negligible, even though the absolute proton NTCP was generally lower. This is because substantially lowering the dose to organs at risk will not lower the rate of complications if that rate is already negligible. A caveat is that late effects of radiation are largely determined by modeling. If the true incidence and risk of radiation has been under estimated, then the clinical benefit of protons from reduction of normal tissue radiation exposure is being under appreciated as well.
Based upon concern of the stochastic risk of radiation related toxicities, delivering less dose to normal tissue will ultimately result in lower risk of late adverse effects. A cumulative reduction in treatment related side effects is expected to translate to improved overall patient quality of life. Minimizing critical structure dose and reducing normal tissue exposure is an important focus of all radiation therapy and protons afford this advantage.
Previous studies of IMRT versus proton therapy for different CNS tumors have shown similar results. In a study comparing 3D conformal photon therapy (3DCRT), stereotactic arc therapy, IMRT and proton radiotherapy for five acoustic neuromas, five meningiomas and two pituitary adenomas, it was concluded after DVH analysis that proton irradiation was superior to all other treatment choices for uniformity and conformity. While all techniques were adequate for target coverage, proton therapy was the suggested treatment of choice for these benign tumors in order to reduce toxicity and risk of secondary malignancy, in light of the longer life expectancy of these patient populations (13). The increased conformality and reduced critical structure dose seen from proton therapy in this analysis are in line with the results of our study, as can be seen in Figures 1 and 2 . The proton plans show tighter dose fall off and the DVHs display reduced critical structure doses for the proton plans when compared to the IMRT plans.
In an additional study that compared proton therapy to photon stereotactic conformal therapy with micro-multileaf collimators for seven different cases of intracranial tumors, ranging from optic gliomas, cavernous sinus meningiomas, skull base chordomas and others, it was shown that while for simple tumors there was no advantage to one technique over the other, for more complexly shape lesions or tumors in close proximity to critical structures, proton therapy was superior in achieving the desired dose to targets and had better conformality (14). One limitation to this study was the lack of clinical correlate with the dosimetric differences although the physical data was suggestive of proton superiority. In Figure 1 , the advantageous dose fall-off for protons allow for better sparing of the brainstem, optic chiasm and right cochlea. The corresponding IMRT plan does avoid these structures through designed constraints, but the tradeoff of a larger low dose bath is seen.
It has been suggested that proton therapy should not be compared to IMRT until a proton modality of similar intensity variation is available, such as intensity modulated proton therapy (IMPT). Based upon this desire of equivalent planning technology, one study chose to compare standard 3D conformal proton plans as used in our study to photon-based 3DCRT for nine pediatric patients with various CNS malignancies and found that in order to achieve the same conformity with 3DCRT as with protons, the dose to surrounding critical normal tissue would be 3-5 times greater with 3DCRT plans as compared to proton plans (15).
The above comparison study points out a limitation in our analysis, in that passively scattered proton therapy is compared to IMRT, rather than a comparison of IMPT versus IMRT or a comparison of photon 3DCRT versus proton 3DCRT. While our study is not an ideal comparison by modality, it is a just comparison in that it evaluates the two most advanced methods of radiation therapy that are currently clinically utilized at our center and representative of the current practice of most photon and proton treatment facilities. In the future when IMPT is more prevalent in proton therapy facilities for routine clinical practice, this form of proton therapy can be more appropriately compared to IMRT. In the interim, even while the full clinical potential of proton therapy is not yet realized, its dosimetric advantages are clear. It is expected that IMPT will improve the benefit of proton therapy beyond that currently observed by passively scattered proton beam radiation by the significant reduction of neutron production.
Overall, the methods of proton dose delivery take advantage of sharp distal and lateral beam profiles and the weighted dose deposition at end range. There are disadvantages to proton therapy, as passive scattering is the dominant current method of delivery, such as the limited modulation variability. In the near future, the clinical application of pencil beam scanning will make it possible for a greater potential of proton therapy to be explored.
Conclusion
Based upon the modeling results of this eleven patient study comparing passively scattered proton radiation therapy to IMRT for LGG, it is estimated that proton therapy reduces the EUD doses to surrounding normal structures by half and IMRT has a twofold higher risk of secondary intracranial tumors when compared to proton therapy. Due to the conformal nature of both radiation treatment techniques and moderate target dose delivered in this patient population, the NTCP is negligible for both modalities in most cases. The benefit of proton therapy over IMRT in terms of normal tissue toxicity appears to be most substantial in patients with tumors in close proximity to critical structures. The true clinical relevance of the advantages and disadvantages seen in this comparison of the radiation treatment modalities remains to be seen.
